LB-3. Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated With Thrombocytopenia. N. Afdhal; G. Dusheiko; E. G. Giannini; P. Chen; K. Han; A. Moshin; M. Rodriguez-Torres; S. Rugina; E. Lawitz; M. L. Shiffman; G. Tayyab; F. Poordad; Y. Mostafa Kamel; A. Brainsky; J. Geib; S. Y. Vasey; R. Patwardhan; F. M. Campbell; D. Theodore
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.